Erythropoietin improves long-term outcomes in patients with acute kidney injury after coronary artery bypass grafting

Journal of Korean Medical Science

Volumn 27, Issue 5, 2012, Pages 506-511

  Oh, Se Won ^a   Chin, Ho Jun ^a,b   Chae, Dong Wan ^a,b   Na, Ki Young ^a,b  

^a Seoul National University Bundang Hospital   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

Author keywords

Erythropoietin; Mortality; Neutrophil gelatinase associated lipocalin protein

Indexed keywords

ACUTE PHASE PROTEIN; ANTIANEMIC AGENT; BIOLOGICAL MARKER; CREATININE; ERYTHROPOIETIN; LCN2 PROTEIN, HUMAN; LIPOCALIN; ONCOPROTEIN; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT PROTEIN;

ACUTE KIDNEY FAILURE; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; KAPLAN MEIER METHOD; MALE; MIDDLE AGED; MORTALITY; PLACEBO EFFECT; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RECEIVER OPERATING CHARACTERISTIC; RISK FACTOR; TREATMENT OUTCOME; URINE;

ACUTE KIDNEY INJURY; ACUTE-PHASE PROTEINS; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CORONARY ARTERY BYPASS; CREATININE; DOUBLE-BLIND METHOD; ERYTHROPOIETIN; FEMALE; HEMATINICS; HUMANS; KAPLAN-MEIER ESTIMATE; LIPOCALINS; MALE; MIDDLE AGED; PLACEBO EFFECT; PROSPECTIVE STUDIES; PROTO-ONCOGENE PROTEINS; RECOMBINANT PROTEINS; RISK FACTORS; ROC CURVE; TREATMENT OUTCOME;

EID: 84862860388     PISSN: 10118934     EISSN: 15986357     Source Type: Journal    
DOI: 10.3346/jkms.2012.27.5.506     Document Type: Article

References (30)

1. Maxwell PH, Osmond MK, Pugh CW, Heryet A, Nicholls LG, Tan CC, Doe BG, Ferguson DJ, Johnson MH, Ratcliffe PJ. Identification of the renal erythropoietin-producing cells using transgenic mice. Kidney Int 1993; 44: 1149-62.
2. Weidemann A, Johnson RS. Nonrenal regulation of EPO synthesis. Kidney Int 2009; 75: 682-8.
3. Warren JS, Zhao Y, Yung R, Desai A. Recombinant human erythropoietin suppresses endothelial cell apoptosis and reduces the ratio of Bax to Bcl-2 proteins in the aortas of apolipoprotein E-deficient mice. J Cardiovasc Pharmacol 2011; 57: 424-33.
4. Toba H, Nakashima K, Oshima Y, Kojima Y, Tojo C, Nakano A, Wang J, Kobara M, Nakata T. Erythropoietin prevents vascular inflammation and oxidative stress in subtotal nephrectomized rat aorta beyond haematopoiesis. Clin Exp Pharmacol Physiol 2010; 37: 1139-46.
5. Malgorzewicz S, Lichodziejewska-Niemierko M, Lizakowski S, Liberek T, Lysiak-Szydlowska W, Rutkowski B. Oxidative stress, inflammation and nutritional status during darbepoetin alpha treatment in peritoneal dialysis patients. Clin Nephrol 2010; 73: 210-5.
6. Ozawa T, Toba K, Suzuki H, Kato K, Iso Y, Akutsu Y, Kobayashi Y, Takeyama Y, Kobayashi N, Yoshimura N, et al. Single-dose intravenous administration of recombinant human erythropoietin is a promising treatment for patients with acute myocardial infarction: randomized controlled pilot trial of EPO/AMI-1 study. Circ J 2010; 74: 1415-23.
7. Haljan G, Maitland A, Buchan A, Arora RC, King M, Haigh J, Culleton B, Faris P, Zygun D. The erythropoietin neuroprotective effect: assessment in CABG surgery (TENPEAKS): a randomized, double-blind, placebo controlled, proof-of-concept clinical trial. Stroke 2009; 40: 2769-75.
8. Song YR, Lee T, You SJ, Chin HJ, Chae DW, Lim C, Park KH, Han S, Kim JH, Na KY. Prevention of acute kidney injury by erythropoietin in patients undergoing coronary artery bypass grafting: a pilot study. Am J Nephrol 2009; 30: 253-60.
9. Johnson DW, Pat B, Vesey DA, Guan Z, Endre Z, Gobe GC. Delayed administration of darbepoetin or erythropoietin protects against ischemic acute renal injury and failure. Kidney Int 2006; 69: 1806-13.
10. Lee DW, Kwak IS, Lee SB, Song SH, Seong EY, Yang BY, Lee MY, Sol MY. Post-treatment effects of erythropoietin and nordihydroguaiaretic acid on recovery from cisplatin-induced acute renal failure in the rat. J Korean Med Sci 2009; 24: S170-5.
11. Kim SS, Lee KH, Sung DK, Shim JW, Kim MJ, Jeon GW, Chang YS, Park WS. Erythropoietin attenuates brain injury, subventricular zone expansion, and sensorimotor deficits in hypoxic-ischemic neonatal rats. J Korean Med Sci 2008; 23: 484-91.
12. Lee JH, Sung DK, Koo SH, Shin BK, Hong YS, Son CS, Lee JW, Chang YS, Park WS. Erythropoietin attenuates hyperoxia-induced lung injury by down-modulating inflammation in neonatal rats. J Korean Med Sci 2007; 22: 1042-7.
13. James MT, Ghali WA, Knudtson ML, Ravani P, Tonelli M, Faris P, Pannu N, Manns BJ, Klarenbach SW, Hemmelgarn BR. Alberta Provincial Project for Outcome Assessment in Coronary Heart Disease (APPROACH) Investigators. Associations between acute kidney injury and cardiovascular and renal outcomes after coronary angiography. Circulation 2011; 123: 409-16.
14. Mehta RH, Honeycutt E, Patel UD, Lopes RD, Shaw LK, Glower DD, Harrington RA, Califf RM, Sketch MH Jr. Impact of recovery of renal function on long-term mortality after coronary artery bypass grafting. Am J Cardiol 2010; 106: 1728-34.
15. Mishra J, Dent C, Tarabishi R, Mitsnefes MM, Ma Q, Kelly C, Ruff SM, Zahedi K, Shao M, Bean J, et al. Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery. Lancet 2005; 365: 1231-8.
16. Haase M, Bellomo R, Devarajan P, Schlattmann P, Haase-Fielitz A. NGAL Meta-analysis Investigator Group. Accuracy of neutrophil gelatinase-associated lipocalin (NGAL) in diagnosis and prognosis in acute kidney injury: a systematic review and meta-analysis. Am J Kidney Dis 2009; 54: 1012-24.
17. Herget-Rosenthal S, Marggraf G, Hüsing J, Göring F, Pietruck F, Janssen O, Philipp T, Kribben A. Early detection of acute renal failure by serum cystatin C. Kidney Int 2004; 66: 1115-22.
18. Schmidt-Ott KM, Mori K, Li JY, Kalandadze A, Cohen DJ, Devarajan P, Barasch J. Dual action of neutrophil gelatinase-associated lipocalin. J Am Soc Nephrol 2007; 18: 407-13.
19. KOSIS. Korean Statistical Information Service. Available at http://kosis. kr/eng/index/index.jsp [accessed on 22 September 2011].
20. Kim SY, Jin DC, Bang BK. Current status of dialytic therapy in Korea. Nephrology (Carlton) 2003; 8: S2-9.
21. Mehta RL, Kellum JA, Shah SV, Molitoris BA, Ronco C, Warnock DG, Levin A, Acute Kidney Injury Network. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care 2007; 11: R31.
22. Rosner MH, Okusa MD. Acute kidney injury associated with cardiac surgery. Clin J Am Soc Nephrol 2006; 1: 19-32.
23. Liangos O, Tighiouart H, Perianayagam MC, Kolyada A, Han WK, Wald R, Bonventre JV, Jaber BL. Comparative analysis of urinary biomarkers for early detection of acute kidney injury following cardiopulmonary bypass. Biomarkers 2009; 14: 423-31.
24. Han WK, Wagener G, Zhu Y, Wang S, Lee HT. Urinary biomarkers in the early detection of acute kidney injury after cardiac surgery. Clin J Am Soc Nephrol 2009; 4: 873-82.
25. Ehrenreich H, Weissenborn K, Prange H, Schneider D, Weimar C, Wartenberg K, Schellinger PD, Bohn M, Becker H, Wegrzyn M, et al. Recombinant human erythropoietin in the treatment of acute ischemic stroke. Stroke 2009; 40: e647-56.
26. Endre ZH, Walker RJ, Pickering JW, Shaw GM, Frampton CM, Henderson SJ, Hutchison R, Mehrtens JE, Robinson JM, Schollum JB, et al. Early intervention with erythropoietin does not affect the outcome of acute kidney injury (the EARLYARF trial). Kidney Int 2010; 77: 1020-30.
27. Munshi R, Johnson A, Siew ED, Ikizler TA, Ware LB, Wurfel MM, Himmelfarb J, Zager RA. MCP-1 gene activation marks acute kidney injury. J Am Soc Nephrol 2011; 22: 165-75.
28. Thrailkill KM, Moreau CS, Cockrell GE, Jo CH, Bunn RC, Morales-Pozzo AE, Lumpkin CK, Fowlkes JL. Disease and gender-specific dysregulation of NGAL and MMP-9 in type 1 diabetes mellitus. Endocrine 2010; 37: 336-43.
29. Nickolas TL, Barasch J, Devarajan P. Biomarkers in acute and chronic kidney disease. Curr Opin Nephrol Hypertens 2008; 17: 127-32.
30. Meijer E, Boertien WE, Nauta FL, Bakker SJ, van Oeveren W, Rook M, van der Jagt EJ, van Goor H, Peters DJ, Navis G, et al. Association of urinary biomarkers with disease severity in patients with autosomal dominant polycystic kidney disease: a cross-sectional analysis. Am J Kidney Dis 2010; 56: 883-95.